Tandem Diabetes Care Inc at Jefferies London Healthcare Conference Transcript
Running the Tandem Diabetes fireside chat. My name is [Young Li]. I'm one of the analysts on the U.S. Medtech team. I'm very pleased to be joined by John Sheridan, President and CEO; and Leigh Vosseller, EVP, CFO and Treasurer.
Thanks for coming to our conference, guys and looking forward to the chat. So I guess maybe we can spend a minute just talking about the insulin pump market, penetration of the opportunity today? And where do you think this therapy is going over time?
Questions & Answers
Sure. Well, first of all, it's nice to be here. I would say that if you look back over the last couple of years, the insulin pump market has been accelerating. If you were to go back as far as 5 or 6 years ago, there was about 25,000 people, who came from MDI therapy annually to pump therapy. And around 2018, we saw that started to accelerate. I think it was largely driven by new technologies in the marketplace, technologies that reduce the burden of diabetes
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |